Abcuro

Anatomical model of human arm and torso showing muscle

Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study

A year after Abcuro raised $200 million to fund a phase 2/3 muscle disease trial of its anti-KLRG1 antibody, the study has flunked all its main goals.

James Waldron Feb 24, 2026 9:15am

Sanofi vaccine vet vaults to GSK—Chutes & Ladders

Jun 13, 2025 8:30am

Abcuro takes $200M series C to fund KLRG1 antibody pivotal trial

Feb 12, 2025 8:30am

Abcuro uses $155M series B to push KLRG1 antibody through clinic

Aug 17, 2023 6:30am

People shaking hands across a desk that has computer and papers on it

Sanofi-backed Abcuro bags $42M to trial KLRG1 immunotherapy

Jan 7, 2021 7:00am